Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Theory-based dyadic co-learning intervention to enhance family resilience in men with prostate cancer and their spouses in Taiwan: protocol for a randomised controlled trial.

BMJ open·2026
Same author

Distinct subtypes of kidney transplant-associated urothelial carcinomas harboring BK polyomavirus integration and aristolochic acid mutational signatures.

Biomedical journal·2026
Same author

Integrative genomic, transcriptomic, and metabolomic profiling of Dillenia suffruticosa.

Scientific reports·2026
Same author

Molecular Mechanisms and Nutritional Modulation in Sarcopenia: A Narrative Review.

Nutrients·2026
Same author

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Science translational medicine·2026
Same author

Makorin Ring Finger Protein 1 Inhibits Cell Proliferation in Renal Angiomyolipoma via the ERK/MAPK Signaling Pathway.

Kidney diseases (Basel, Switzerland)·2026

Related Experiment Video

Updated: Apr 11, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.5K

Mutation signatures implicate aristolochic acid in bladder cancer development.

Song Ling Poon1, Mi Ni Huang2, Yang Choo2

  • 1Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610 Singapore ; Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore, 169857 Singapore.

Genome Medicine
|May 28, 2015
PubMed
Summary

Aristolochic acid (AA) exposure is linked to bladder cancer, particularly in East Asia. This study identifies AA

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

11.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

11.0K

Area of Science:

  • Genomics
  • Cancer Research
  • Toxicology

Background:

  • Aristolochic acid (AA) is a natural compound found in Aristolochia plants, used in traditional medicine.
  • Previous research linked AA-mutagenesis to urothelial and hepatocellular carcinomas.
  • AA's potential role in bladder cancer development was hypothesized.

Purpose of the Study:

  • To investigate the involvement of AA-mutagenesis in bladder cancer.
  • To identify AA exposure signatures in bladder tumor genomes.

Main Methods:

  • Sequencing of bladder tumor genomes from patients with known AA exposure.
  • Exome sequencing and analysis of 11 additional bladder tumors.
  • Analysis of publicly available somatic mutation data from 336 bladder tumors.

Main Results:

  • Strong AA mutational signatures were detected in bladder tumors from patients with known AA exposure.
  • Evidence of AA exposure was found in bladder tumors from Singapore and China.
  • AA exposure may be a more widespread cause of bladder cancer than previously recognized.

Conclusions:

  • Somatic mutation spectra can reveal mutagenic exposures like AA.
  • AA exposure appears more prevalent in bladder cancer in Eastern populations using traditional herbal medicine.
  • AA exposure represents a significant public health concern for both primary and secondary cancer prevention.